Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience

Cancer Cytopathology

Volumn 122, Issue 7, 2014, Pages 527-535

  Rossi, Esther Diana ^a   Martini, Maurizio ^a   Capodimonti, Sara ^a   Cenci, Tonia ^a   Straccia, Patrizia ^a   Angrisani, Basilio ^a   Ricci, Costantino ^a   Lanza, Paola ^a   Lombardi, Celestino Pio ^a   Pontecorvi, Alfredo ^a   Larocca, Luigi Maria ^a   Fadda, Guido ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

BRAF mutation; Immunochemistry; Liquid based cytology; Thyroid papillary carcinoma; VE1 immunomarker

Indexed keywords

BRAF MUTATION; IMMUNOCHEMISTRY; LIQUID-BASED CYTOLOGY; THYROID PAPILLARY CARCINOMA; VE1 IMMUNOMARKER;

ADULT; AGED; BIOPSY, NEEDLE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84905968600     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21416     Document Type: Article

References (39)

1. Bosmuller H, Fischer A, Pham DL, et al. Detection of the BRAF V600E mutation in serous ovarian tumors: A comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol. 2013;44:329-335.
2. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011; 122:11-19.
3. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signalling pathway by oncogenic mutations of BRAF. Cell. 2004;116:855-867.
4. Ciampi R, Zhu Z, Nikiforov YE. BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization. Endocr Pathol. 2005;16:99-105.
5. Correia-Rodrigues HG, Nogueira De Pontes AA, Adan LFF. Use of molecular markers in samples obtained from preoperative aspiration of thyroid. Endocr J. 2012;59:417-424.
6. Rossi ED, Martini M, Capodimonti S, et al. Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma. Eur J Endocrinol. 2013;168:853-859.
7. Rossi ED, Martini M, Capodimonti S, et al. BRAF (V600E) mutation analysis on LBC-processed aspiration biopsies predicts bilaterality and nodal involvement in papillary thyroid microcarcinoma. Cancer Cytopathol. 2013;121:291-297.
8. Xing M. Braf mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007; 28:742-762.
9. Kim TH, Park YJ, Lim JA, et al. The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer. Cancer Cytopathol. 2012;118: 1764-1773.
10. Elisei R, Ugolini C, Viola D, et al. BRAF mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93:3943-3950.
11. Nikiforova MN, Nikiforov Y. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009;19:1351-1361.
12. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092-2098.
13. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance=atypia of undetermined significance." Cancer Cytopathol. 2010;118:17-23.
14. Kim SK, Kim DL, Han HS, et al. Pyrosequencing analysis for detection of a BRAFV600E mutation in a FNAB specimen of thyroid nodules. Diagn Mol Pathol. 2008;17:118-125.
15. Yeo MK, Liang ZL, Oh T, et al. Pyrosequencing cutoff value identifying BRAF V600E mutation in fine needle aspiration samples of thyroid nodules. Clin Endocrinol. 2011;75:555-560.
16. Oler G, Camacho CP, Hojaij FC, et al. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res. 2008;14:4735-4742.
17. Ghossein RA, Katabi N, Fagin JA. Immunohistochemical detection of mutated BRFV600E supports the clonal origin of BRAF induced thyroid cancers along the spectrum of disease progression. J Clin Endocrinol Metab. 2013;98 E1414-E4121.
18. Sinicrope FA, Smyrk TC, Tougeron D, et al. Mutation specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. Cancer. 2013;119:2765-2770.
19. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAFV600E in 1.120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012;123:223-233.
20. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation on melanoma. Am J Surg Pathol. 2013;37:61-65.
21. Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma and gliomas. Hum Pathol. 2013;44:2563- 2570.
22. Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 2012;36:844-850.
23. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2009;19:1159-1165.
24. Fadda G, Basolo F, Bondi A, et al;SIAPEC-IAP Italian Consensus Working Group. Cytological classification of thyroid nodules. Pathologica. 2010;102:405-408.
25. British Thyroid Association, Royal College of Physicians. 2007 Guidelines for the Management of Thyroid Cancer. 2nd ed. London, United Kingdom: British Thyroid Association, Royal College of Physicians; 2007.
26. Mathur A, Weng J, Moses W. A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsies. Surgery. 2010;148:1176-1177.
27. Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011;135:569-577.
28. Musholt TJ, Fottner C, Weber M, et al. Detection of papillary carcinoma by analysis of BRAF and RET=PTC1 mutations in fine needle aspiration biopsies of thyroid nodules. World J Surg. 2010; 34:2595-2603.
29. Eszlinger M, Paschke R. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns. J Mol Cell Endocrinol. 2010;322:29-37.
30. Moses W, Weng J, Sansano I, et al. Molecular testing for somatic mutations improves the accuracy of thyroid fine needle aspiration biopsy. World J Surg. 2010;34:2589-2594.
31. Basolo F, Torregrossa L, Giannini R, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: Analysis of 1060 cases. J Clin Endocrinol Metab. 2010;95:4197-4205.
32. Martini M, Teofili L, Cenci T, et al. A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica. 2008;93:1068-1071.
33. Cochand-Priollet B, Dahan H, Laloi-Michelin M, et al. Immunocytochemistry with cytokeratin 19 and HBME-1 increases the diagnostic accuracy of thyroid fine-needle aspirations. Preliminary report of 150 liquid-based fine needle aspirations with histological control. Thyroid. 2011;21:1067-2073.
34. Yip L, Farris C, Kabaker AS, et al. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab. 2012;97:1905-1912.
35. Fadda G, Rossi ED, Raffaelli M, et al. Follicular thyroid neoplasms can be classified as low and high risk according to HBME-1 and Galectin 3 expression on liquid based fine needle cytology. Eur J Endocrinol. 2011;165:447-453.
36. Zimmermann AK, Camerisch U, Rechsteiner MP, Bode-Lesniewska B, Rossle M. Value of immunohistochemistry in detection of BRAF V600E mutations in fine needle aspiration biopsies of papillary thyroid carcinoma. Cancer Cytopathol. 2014;122:48-58.
37. Bansal M, Ghandi M, Ferris RL, et al. Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma. Am J Surg Pathol. 2013;37:1586-1591.
38. Park SY, Park YJ, Lee YJ, et al. Analysis of differential BRAF (V600E) mutational status in multifocal papillary thyroid carcinoma. Evidence of independent clonal origin in distinct tumor foci. Cancer. 2006;107:1831-1838.
39. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinical-pathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:4085-4090.